Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression

Mandi Murph, Gordon Mills

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

The bioactive lipids lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), the enzymes that generate and degrade them, and the receptors that receive their signals are all potential therapeutic targets in cancer. LPA and S1P signalling pathways can modulate a range of cellular processes that contribute to tumourigenesis, such as proliferation and motility, and components of the signalling pathways often show aberrant expression and altered activity upon malignant transformation. This article reviews LPA- and S1P-mediated activities that might contribute to the aetiology of cancer, and examines the potential of the many antagonists that have been developed to inhibit LPA and S1P signalling pathways. In addition, the outcomes of various clinical trials using LPA- and S1P-associated targets in cancer and other diseases are described, and future directions are discussed.

Original languageEnglish (US)
Pages (from-to)1-18
Number of pages18
JournalExpert Reviews in Molecular Medicine
Volume9
Issue number28
DOIs
StatePublished - Oct 1 2007
Externally publishedYes

Fingerprint

Tumors
Lipids
Neoplasms
sphingosine 1-phosphate
lysophosphatidic acid
Clinical Trials
Enzymes
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)
  • Molecular Medicine

Cite this

Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression. / Murph, Mandi; Mills, Gordon.

In: Expert Reviews in Molecular Medicine, Vol. 9, No. 28, 01.10.2007, p. 1-18.

Research output: Contribution to journalArticle

@article{32191c6667024ab39cdd3c29482d00c7,
title = "Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression",
abstract = "The bioactive lipids lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), the enzymes that generate and degrade them, and the receptors that receive their signals are all potential therapeutic targets in cancer. LPA and S1P signalling pathways can modulate a range of cellular processes that contribute to tumourigenesis, such as proliferation and motility, and components of the signalling pathways often show aberrant expression and altered activity upon malignant transformation. This article reviews LPA- and S1P-mediated activities that might contribute to the aetiology of cancer, and examines the potential of the many antagonists that have been developed to inhibit LPA and S1P signalling pathways. In addition, the outcomes of various clinical trials using LPA- and S1P-associated targets in cancer and other diseases are described, and future directions are discussed.",
author = "Mandi Murph and Gordon Mills",
year = "2007",
month = "10",
day = "1",
doi = "10.1017/S1462399407000476",
language = "English (US)",
volume = "9",
pages = "1--18",
journal = "Expert Reviews in Molecular Medicine",
issn = "1462-3994",
publisher = "Cambridge University Press",
number = "28",

}

TY - JOUR

T1 - Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression

AU - Murph, Mandi

AU - Mills, Gordon

PY - 2007/10/1

Y1 - 2007/10/1

N2 - The bioactive lipids lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), the enzymes that generate and degrade them, and the receptors that receive their signals are all potential therapeutic targets in cancer. LPA and S1P signalling pathways can modulate a range of cellular processes that contribute to tumourigenesis, such as proliferation and motility, and components of the signalling pathways often show aberrant expression and altered activity upon malignant transformation. This article reviews LPA- and S1P-mediated activities that might contribute to the aetiology of cancer, and examines the potential of the many antagonists that have been developed to inhibit LPA and S1P signalling pathways. In addition, the outcomes of various clinical trials using LPA- and S1P-associated targets in cancer and other diseases are described, and future directions are discussed.

AB - The bioactive lipids lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), the enzymes that generate and degrade them, and the receptors that receive their signals are all potential therapeutic targets in cancer. LPA and S1P signalling pathways can modulate a range of cellular processes that contribute to tumourigenesis, such as proliferation and motility, and components of the signalling pathways often show aberrant expression and altered activity upon malignant transformation. This article reviews LPA- and S1P-mediated activities that might contribute to the aetiology of cancer, and examines the potential of the many antagonists that have been developed to inhibit LPA and S1P signalling pathways. In addition, the outcomes of various clinical trials using LPA- and S1P-associated targets in cancer and other diseases are described, and future directions are discussed.

UR - http://www.scopus.com/inward/record.url?scp=35448989224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35448989224&partnerID=8YFLogxK

U2 - 10.1017/S1462399407000476

DO - 10.1017/S1462399407000476

M3 - Article

VL - 9

SP - 1

EP - 18

JO - Expert Reviews in Molecular Medicine

JF - Expert Reviews in Molecular Medicine

SN - 1462-3994

IS - 28

ER -